EDTXF Spectral Diagnostics

-

Spectral Diagnostics Reported Earnings

Friday, November 6, 2026 · 12:00 AM ET

Spectral Diagnostics (EDTXF) reported a loss of $0.01 per share on revenue of $0.20 million for the . . Revenue fell 59.80% compared to the same quarter a year ago.

Spectral Medical Inc. develops and commercializes theranostic treatment for severe sepsis. The company's products include Endotoxin Activity Assay, a rapid diagnostic test for detection of components of gram negative bacterial cell wall; and Toraymyxin, a therapeutic hemoperfusion device for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral Medical Inc., formerly known as Spectral Diagnostics Inc., is headquartered in Toronto, Canada.

Earnings Whisper Grade —
Power Rating—
Reported Earnings
($0.01)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth87.5 %
Reported Revenue
$0.20M
Revenue Estimate
—
Revenue Surprise
Revenue Growth-59.8 %